The drug is isotretinoin, sold for decades under the brand name Accutane and now available as generics like Claravis, Amnesteem, and Absorica. It remains one of the most teratogenic medications in routine clinical use — meaning it causes severe birth defects at alarming rates. Between 20 and 35 percent of infants exposed to isotretinoin in the womb are born with major malformations, a condition formally known as Fetal Retinoid Syndrome. Up to 40 percent of exposed pregnancies end in miscarriage. Despite these risks, over one million prescriptions are filled annually in the United States, making isotretinoin the 264th most commonly prescribed medication in the country as of 2021.
What makes this story more than a straightforward drug safety issue is the tension between isotretinoin’s extraordinary effectiveness and its capacity for devastating harm. The drug cures severe cystic acne in roughly 85 percent of patients after a single course — a success rate no other acne treatment comes close to matching. The FDA has kept it on the market under strict risk management protocols, most notably the iPLEDGE program, which requires pregnancy testing, dual contraception, and provider registration. But in February 2026, the FDA loosened several iPLEDGE requirements, reigniting debate about whether convenience is being prioritized over safety. This article examines the birth defect risks in detail, the neurocognitive damage that can occur even without visible physical defects, the regulatory history, and what all of this means for patients and families navigating the decision.
Table of Contents
- Why Does Isotretinoin Still Get Prescribed Despite Causing Birth Defects?
- The Scope of Neurocognitive Damage Most People Never Hear About
- iPLEDGE — The Safety Net That Catches Some but Not All
- The 2026 FDA Rule Changes — More Access, but at What Cost?
- The Legal Aftermath and Why It Went Quiet
- What Families and Caregivers Should Know
- The Future of Isotretinoin Regulation
- Conclusion
Why Does Isotretinoin Still Get Prescribed Despite Causing Birth Defects?
The short answer is that nothing else works as well for severe acne. Isotretinoin is a powerful retinoid — a derivative of vitamin A — that the fda originally approved on May 7, 1982, under the brand name Accutane, manufactured by Roche. It was designed specifically for severe, recalcitrant nodular acne, the kind that leaves deep scars, resists antibiotics, and can cause lasting psychological harm. For patients who have exhausted every other option — topical retinoids, oral antibiotics, hormonal therapies — isotretinoin often represents the only realistic path to clear skin. With an approximate 85 percent cure rate after a single course, according to the American Academy of Dermatology, it is not a marginal improvement over alternatives. It is in a category by itself. The calculus changes entirely, however, when a patient can become pregnant. The drug’s teratogenicity was recognized almost immediately after approval, and the warning label is explicit: isotretinoin is classified as FDA Pregnancy Category X, meaning the risks to a fetus absolutely outweigh any possible benefit.
The specific defects associated with fetal exposure are severe — microtia (small or absent ears), heart defects, hydrocephalus, microcephaly, cleft palate, micrognathia (abnormally small jaw), and thymus gland abnormalities. These are not subtle developmental variations. They are life-altering structural malformations. Roche discontinued the Accutane brand in June 2009, but the reason was economics — falling market share from generic competition and mounting lawsuit costs — not a safety recall. The FDA explicitly determined that the withdrawal was not for safety or efficacy reasons. Generic versions flooded the market and remain widely available today under names like Amnesteem, Claravis, Sotret, Absorica, Absorica LD, Myorisan, and Zenatane. The drug never went away. It simply changed its name.
The Scope of Neurocognitive Damage Most People Never Hear About
The conversation around isotretinoin and pregnancy tends to focus on visible birth defects — the missing ears, the heart malformations. But the neurocognitive damage may be the more insidious outcome, precisely because it can go undetected for years. Research published in PMC indicates that 30 to 60 percent of children exposed to isotretinoin in utero suffer neurocognitive impairments even when they are born without any visible physical defects. These children may appear healthy at birth, pass initial screenings, and only begin showing developmental delays, learning disabilities, or intellectual impairment as they grow. This is particularly relevant for a brain health audience because these neurocognitive effects are permanent. They stem from disrupted brain development during critical gestational windows, and no intervention after birth can fully reverse the damage.
A meta-analysis examining 2,783 women exposed to isotretinoin during pregnancy found a weighted major malformation rate of 15 percent in liveborn infants, but that figure only captures structural abnormalities. The cognitive toll is harder to quantify and likely undercounted, because many affected children are never formally diagnosed or are misattributed to other causes. However, it is important to note a limitation: not every exposed pregnancy results in harm. some children exposed during the earliest days of pregnancy, before organogenesis begins, may escape damage entirely. The risk is not binary. It is probabilistic, and it depends heavily on timing, dosage, and duration of exposure. This is precisely what makes the situation so dangerous — some women who inadvertently become pregnant while on isotretinoin may convince themselves the odds are in their favor, when the stakes are, by any clinical standard, unacceptably high.
iPLEDGE — The Safety Net That Catches Some but Not All
The iPLEDGE program is the FDA’s attempt to square a difficult circle: keep a highly effective drug available while preventing fetal exposure. It is a REMS — a Risk Evaluation and Mitigation Strategy — that requires every patient, prescriber, and pharmacy to register before a single capsule of isotretinoin can be dispensed. For female patients of childbearing potential, the requirements are substantial: two simultaneous forms of contraception, monthly pregnancy tests, and strict prescription timing windows. The system is designed to make it functionally impossible to take isotretinoin while pregnant. In practice, the system is far from airtight. Roughly 40 percent of isotretinoin prescriptions written in one year of the iPLEDGE program were denied due to non-compliance with program requirements, according to StatPearls data.
That figure tells two stories simultaneously. On one hand, it shows the system catching potential problems. On the other, it reveals how frequently patients and providers struggle to navigate the program’s bureaucratic requirements — missed test windows, registration errors, pharmacy delays — many of which have nothing to do with actual pregnancy risk. Male patients and women who are not of childbearing potential have historically been subjected to the same documentation burdens, creating frustration that critics argue undermines compliance where it matters most. The program has also been criticized for placing a disproportionate burden on patients in rural areas, those without reliable internet access for the online portal, and those whose pharmacies have difficulty navigating the verification system. A safety program that is too cumbersome risks being circumvented, which defeats its entire purpose.
The 2026 FDA Rule Changes — More Access, but at What Cost?
On February 9, 2026, the FDA approved modifications to the iPLEDGE program, set to take effect on August 9, 2026. The changes are intended to reduce the administrative burden on patients and providers while maintaining the core safety framework. Three major changes stand out. First, at-home pregnancy tests are now permitted during and after treatment, though pre-treatment tests still require a clinical or lab setting. Second, the 19-day lockout period has been eliminated — patients who miss their seven-day prescription pickup window will no longer be forced to wait for a repeat pregnancy test before refilling. Third, monthly counseling documentation requirements have been removed for patients who cannot become pregnant. The tradeoff here is real and worth examining honestly.
The lockout elimination, for example, addresses a genuine problem: patients who missed a narrow pickup window through no fault of their own — a pharmacy closure, a scheduling conflict — were forced into a cycle of additional testing and delay that could interrupt treatment for weeks. Dermatologists and patient advocates had pushed for this change for years. However, the shift to at-home pregnancy testing introduces a variable the system previously controlled. Lab-based tests are administered and verified by third parties. At-home tests rely on the patient to perform the test correctly and report the result honestly. Most patients will do exactly that. But the iPLEDGE system exists precisely because the consequences of the rare failure are catastrophic. The question is whether these changes represent a sensible recalibration or the beginning of a regulatory loosening that could, over time, erode the safeguards that have prevented an unknowable number of birth defects since iPLEDGE’s implementation.
The Legal Aftermath and Why It Went Quiet
Isotretinoin’s legal history is substantial but largely concluded. Previous Accutane litigation produced $56 million in jury verdicts, though those verdicts were later overturned on appeal. In 2018, the New Jersey Supreme Court dismissed 532 lawsuits related to the drug. The litigation primarily centered on allegations that Roche failed to adequately warn patients about risks, particularly inflammatory bowel disease — not birth defects, which were always clearly labeled. As of 2026, no law firms are known to be actively taking new Accutane cases, and the litigation has largely wound down. This does not mean the drug is without ongoing risk.
It means the legal system has, for the moment, moved on. For patients and families affected by fetal retinoid syndrome, the absence of active litigation can feel like abandonment — the legal infrastructure that might have provided recourse or drawn public attention to ongoing prescribing concerns has largely dissolved. A warning worth noting: the end of litigation sometimes creates a false impression that a drug’s controversies have been resolved. They have not. The birth defect risk remains exactly what it was in 1982. The only thing that has changed is the legal landscape.
What Families and Caregivers Should Know
For families in the dementia and brain health community, the isotretinoin story carries a specific relevance. The neurocognitive impairments caused by fetal retinoid exposure can present challenges that last a lifetime, and caregivers may find themselves supporting adults whose developmental disabilities trace back to a prenatal drug exposure that occurred decades ago.
A child born in the late 1980s or 1990s, before the iPLEDGE program existed, may now be an adult in their thirties or forties dealing with cognitive limitations whose origin was never properly identified. If you are a caregiver or family member of someone with unexplained developmental or cognitive challenges, and there is any history of isotretinoin use during pregnancy, it is worth raising this with a medical provider. Fetal retinoid syndrome is a recognized diagnosis listed by the National Organization for Rare Disorders, and identifying it — even late — can help shape appropriate support and care planning.
The Future of Isotretinoin Regulation
The February 2026 iPLEDGE modifications signal a regulatory direction that prioritizes patient access and convenience, and dermatology groups have largely welcomed the changes. But the underlying tension is unlikely to disappear.
As long as isotretinoin remains the gold standard for severe acne — and no comparably effective alternative exists — regulators will be balancing a drug that transforms lives against one that can permanently damage them. Research into alternative acne treatments, including targeted biologics and novel retinoids with lower teratogenic profiles, continues but has not yet produced a viable replacement. Until it does, isotretinoin will remain both indispensable and dangerous, and the systems designed to manage that danger will continue to be tested, modified, and debated.
Conclusion
Isotretinoin is a drug defined by contradictions. It is the most effective treatment available for severe acne, with cure rates around 85 percent, and it is also one of the most dangerous medications routinely prescribed, causing major birth defects in 20 to 35 percent of exposed pregnancies and miscarriage in up to 40 percent. The iPLEDGE program has prevented an untold number of fetal exposures, but it has also been criticized as burdensome and imperfect. The FDA’s 2026 decision to loosen certain requirements reflects an ongoing effort to find the right balance, though whether that balance has been struck remains an open question. For patients considering isotretinoin, the decision should never be made casually.
For women of childbearing potential, the contraception and testing requirements are not bureaucratic formalities — they are the only barrier between a skin treatment and irreversible fetal harm. For caregivers and families in the brain health space, understanding the long-term neurocognitive consequences of fetal retinoid exposure can help explain developmental challenges that might otherwise remain a mystery. The drug works. The drug is dangerous. Both things remain true, and neither cancels out the other.
